Cancer Stem Cells

Curt I. Civin, MD, is the Associate Dean for Research and the Founding Director of the Center for Stem Cell Biology & Regenerative Medicine at the University of Maryland School of Medicine. Prior to joining the University of Maryland, Dr. Civin spent 30 years at Johns Hopkins University School of Medicine leading research and clinical pediatric oncology. In addition to holding 27 biomedical patents, Dr. Civin has received wide recognition for his groundbreaking discovery of the CD34 antigen, and isolation of CD34+ stem cells opened entirely new approaches to leukemia treatment and stem cell transplantation. Dr. Civin has lectured around the world, published more than 250 articles and book chapters, received many awards, and served in leadership positions of multiple distinguished committees and editorial boards.Tami J. Kingsbury, PhD, is Assistant Professor of Physiology in the Center for Stem Cell Biology & Regenerative Medicine at the University of Maryland School of Medicine. Dr. Kingsbury has extensive background in genetics and molecular biology. She discovered a novel family of calcineurin regulatory factors (RCANs) conserved from yeast to humans, now implicated in diverse human cancers. She helped develop a functional high throughput screen to identify microRNAs capable of regulating leukemia cell growth and differentiation. Her current research is focused on dissecting the role of the PAX-SIX-EYA-DACH (PSEDN) transcriptional network in leukemias. She is a scientific co-founder of 3DBioWorks, whose goal is to develop 3D bioreactors to grow normal and leukemic stem cells. In 2018 she became leader of CRISPR Services within the University of Maryland Cancer Center Translational Shared Services laboratory.MinJung Kim, PhD, is Research Associate in the Center for Stem Cell Biology & Regenerative Medicine at the University of Maryland School of Medicine. Dr. Kim has broad expertise in cell and molecular biology. Dr. Kim's research focuses on investigating the

1. Regulation of cancer stem cell properties by SIX1, a member of the PAX-SIX-EYA-DACH network Tami J. Kingsbury, MinJung Kim and Curt I. Civin 2. Dormancy and cancer stem cells: An enigma for cancer therapeutic targeting Sarmistha Talukdar, Praveen Bhoopathi, Luni Emdad, Swadesh Das, Devanand Sarkar and Paul B. Fisher 3. Clonal hematopoiesis: Pre-cancer PLUS Alexander J. Silver and Siddhartha Jaiswal 4. Assays for functionally defined normal and malignant mammary stem cells Syed M. Musheer Aalam, Philip A. Beer and Nagarajan Kannan 5. Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy Lisha Xiang and Gregg L. Semenza 6. Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment Aksinija A. Kogan, Rena G. Lapidus, Maria R. Baer and Feyruz V. Rassool